For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Edaravone, sold as under the brand names Radicava and Radicut, is an intravenous medication used to help with recovery following a stroke and to treat amyotrophic lateral sclerosis (ALS).
The label carries a warning about the potential for hypersensitivity reactions to edaravone, and adverse effects include bruising, gait disturbances, headache, skin inflammation, eczema, problems breathing, excess sugar in urine, and fungal skin infections.
The mechanism by which edaravone might be effective is unknown. The drug is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS.
The Edaravone market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Edaravone industry, and breaks down according to the type, application, and consumption area of Edaravone. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Edaravone in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Edaravone market covered in Chapter 11:
Taj Pharmaceuticals Ltd.
Simcere
Mitsubishi Tanabe Pharma
Sun Pharmaceutical Industries Ltd.
Piramal Healthcare
Unichem Laboratories Ltd
UCB India Ltd
In Chapter 3, on the basis of types, the Edaravone market from 2018 to 2028 is primarily split into:
Oral
Injection
In Chapter 4, on the basis of applications, the Edaravone market from 2018 to 2028 covers:
Hospital
Clinic
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028